CLINUVEL PHARMACEUTICALS LIMITED - Charts / Financials

3.44%

$9.83

Market Cap $492.7M

Healthcare Biotechnology

Clinuvel Pharmaceuticals Limited is an Australia-based global specialty pharmaceutical... Clinuvel Pharmaceuticals Limited is an Australia-based global specialty pharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Company’s pharmaceuticals product development includes PRENUMBRA and NEURACTHEL. Its PhotoCosmetics product development includes CYACELLE and DNA Repair Assist and Melanogenesis. PRENUMBRA is a formulation of afamelanotide designed to provide a flexible dose in identified patient groups. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH).More

ASX:AFP

Could this ASX stock become the next Pfizer? A look at AFT Pharmaceuticals (ASX:AFP). With biotech stocks broadly having a strong run in 2025, and with more of the year ahead, investors are still looking for stocks in the sector with room to run.

REFRESH

Day
Open	$10.18		Day High	$10.18		Day Low	$9.75
Daily Volume	140250

Bids				Sellers
Number	Price	Volume		Number	Price	Volume
1	$9.83	9965		1	$9.89	370

Directors & Senior Management

Mr. Lachlan Hay	Acting Chief Executive Officer, Chief Operating Officer
Mr. Peter Vaughan	Chief Financial Officer
Dr. Rose Quadbeck-Diel	Senior Vice President - Regulatory Affairs
Dr. Dennis J. Wright	Chief Scientific Officer
Ms. Antonella Colucci	Vice President - Commercial Affairs
Mr. Malcolm Bull	Head of Australian Operations and Investor Relations
Dr. Azza Hamila	Head of Quality Assurance and Drug Safety
Dr. Emilie Rodenburger	Director - Global Clinical Affairs
Dr. Linda Teng	Director of North American Operations
Ms. Claire Newstead-Sinclair	Company Secretary
Prof. Jeffrey V. Rosenfeld	Non-Executive Chairman of the Board
Dr. Pearl E. Grimes	Non-Executive Director
Mr. Matthew Pringle	Non-Executive Director
Mr. Guy van Dievoet	Non-Executive Director
Dr. Karen A. Agersborg	Non-Executive Independent Director

Data source: Refinitiv

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $9.83		Change -0.350(3.44%)		Mkt cap ! $492.7M

Open	High	Low	Value	Volume
$10.18	$10.18	$9.75	$1.391M	140.2K

Buyers (Bids)

No.	Vol.	Price($)
1	9965	$9.83

Sellers (Offers)

Price($)	Vol.	No.
$9.89	370	1

View Market Depth

No.	Vol.	Price($)
1	244	9.810
3	758	9.800
1	790	9.770
9	6875	9.750
3	221	9.700

Price($)	Vol.	No.
10.000	280	1
10.090	1000	1
10.200	1000	1
10.300	8649	2
10.400	1728	2

Last trade - 16.10pm 13/06/2025 (20 minute delay)

CUV (ASX) Chart

CLINUVEL PHARMACEUTICALS LIMITED - Charts / Financials

Directors & Senior Management

Buyers (Bids)

Sellers (Offers)

Top Stories